Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

Bristol-Myers Squibb (BMS) building

BMS signs $1.74bn deal to boost immuno-oncology portfolio

Gainsaccess to Five Prime Therapeutics CSF1R antibody programme

- PMLiVE

BMS promotes Paul Biondi to head of business development

He willnow lead the development of its strategic partnerships

- PMLiVE

AZ halts durvalumab combination trials on safety grounds

Saysmove is a precautionary step after respiratory disease reports

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

- PMLiVE

BMS recruits Jack Huston for European Lung cancer campaign

TheBoardwalk Empire actor will work with the firm on an awareness drive

Bristol-Myers Squibb (BMS) building

BMS bags US approval for Opdivo and Yervoy combo

Marks first approval for joint use of two immuno-oncology drugs

- PMLiVE

Novartis’ Cosentyx effective in psoriatic arthritis study

Further supports drugs ability to reduce progression of damage to joints

Bristol-Myers Squibb (BMS) building

Opdivo a breakthrough in kidney cancer, says FDA

BMSmoves closer to US approval of its checkpoint inhibitor cancer immunotherapy

- PMLiVE

AZ opens new research centre with Cancer Research UK

MedImmune partners with CRUK in Cambridge-based R&D hub

AZ signs £11.5m bioinformatics deal with Manchester University

Five-year programme will focus on personalised health research

- PMLiVE

FDA approval keeps AZ on track with ambitious Brilinta plans

Receives additional indication for use in heart attack patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links